Evidence map›Paper›PMID 26981246›Full record

ArticleJournal for immunotherapy of cancer2016

A role for pre-mNK cells in tumor progression.

Carolyn Rosinsky, Paul Andrew Antony

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. OMIP-095: 40-Color spectral flow cytometry delineates all major leukocyte populations in murine lymphoid tissues.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2023
    Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Carolyn RosinskyProgram in Molecular Medicine, University of Maryland School of Medicine, Baltimore, MD 21201 USA ; Department of Pathology, University of Maryland School of Medicine, Baltimore, MD 21201 USA.
Paul Andrew AntonyDepartment of Pathology, University of Maryland School of Medicine, Baltimore, MD 21201 USA ; Department of Microbiology and Immunology, University of Maryland School of Medicine, 10 South Pine Street, 734D MSTF, Baltimore, MD 21201 USA ; Tumor Immunology and Immunotherapy Program, University of Maryland Cancer Center, Baltimore, MD 21201 USA.ORCID 0000-0002-9439-667X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The innate and adaptive immune systems have evolved together to fight infection and cancerous tissues. The innate immune system emerges first with the adaptive immune system following, both ostensibly being bridged by dendritic cells (DC). Recently cells have emerged that possess characteristics of both innate and adaptive immune cell qualities, termed interferon-producing killer dendritic cells (IKDCs). These cells have an indistinct origin that is not well understood. They appear to have more NK cell attributes than DC but purportedly can regulate the immune system similar to immunoregulatory NK cells. Because of this, they have been renamed pre-mNK cells (pre-mature NK cells). We argue in this commentary that pre-mNK cells may contribute to cancer recurrence.

Indexed as

CD4+ T cellsIKDCMelanomaPD-L1Pre-mNK cells

Identifiers

PMID26981246
PMCPMC4791770

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.